about
Unmet needs in the management of acute myocardial infarction: role of novel protease-activated receptor-1 antagonist vorapaxarThe antidepressant 5-HT2A receptor antagonists pizotifen and cyproheptadine inhibit serotonin-enhanced platelet functionThe effect of in-hospital acquired thrombocytopenia on the outcome of patients with acute coronary syndromes: A systematic review and meta-analysis.Identification of a New Morpholine Scaffold as a P2Y12 Receptor Antagonist.The evolution of antiplatelet therapy in the treatment of acute coronary syndromes: from aspirin to the present day.Antiplatelet and anticoagulant therapy for atherothrombotic disease: the role of current and emerging agents.ACCF/AHA/SCAI 2013 Update of the Clinical Competence Statement on Coronary Artery Interventional Procedures: a Report of the American College of Cardiology Foundation/American Heart Association/American College of Physicians Task Force on Clinical CAntiplatelet therapy: new pharmacological agents and changing paradigms.Cangrelor: a review on pharmacology and clinical trial development.Novel antiplatelet agents in acute coronary syndrome.Role of Genetic Testing in Patients undergoing Percutaneous Coronary Intervention.Age-Related Changes in Hepatic Function: An Update on Implications for Drug Therapy.Role of New Antiplatelet Drugs on Cardiovascular Disease: Update on Cangrelor.Effects of cangrelor in coronary artery disease patients with and without diabetes mellitus: an in vitro pharmacodynamic investigation.Urinary 11-dehydro-thromboxane B2 levels are associated with vascular inflammation and prognosis in atherosclerotic cardiovascular disease.Simultaneous screening and analysis of antiplatelet aggregation active alkaloids from Rhizoma Corydalis.
P2860
Q27016071-99D9D005-4719-4F34-BF9B-46199F6BA48CQ28539110-A794F2DC-7E32-4394-86F8-CF86B2592DDBQ30244977-7614A32B-2DD4-4D94-B6FE-1124D2AA3F7BQ36114034-AA52FC85-D7C5-4471-A36B-7E09E693976FQ38053481-165DB070-1B24-4192-8A6B-502EE01E92BAQ38101275-BF5D4F14-F1ED-419E-8716-883809058B8AQ38105058-AA925F22-0290-4C6A-98C2-A8FF399C9C4CQ38117743-8B8CDAA7-D613-4634-8F4D-0C5C575EFC4AQ38153779-9CA56EC6-3B5D-400E-9B7D-D4004811C7C3Q38257119-93224F61-43C2-4B9C-97A9-EBD79DFB38A7Q38401281-D0B7B9A5-43D3-4096-8B55-CB96CD0D2837Q38627857-CE173841-531B-480F-9264-1205C302B3AEQ38974706-10E1416F-CEB6-4F41-9F01-E44A6461FC40Q43744458-A0339CD1-6934-4845-8C91-1BE632BAD92EQ47385143-E0BC52A3-499E-48C1-8A53-307F16EE9FA5Q51185892-FBAD2945-E2BF-44A2-AAC1-CCFF31BA2763
P2860
description
2012 nî lūn-bûn
@nan
2012 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
New directions in antiplatelet therapy
@ast
New directions in antiplatelet therapy
@en
New directions in antiplatelet therapy
@nl
type
label
New directions in antiplatelet therapy
@ast
New directions in antiplatelet therapy
@en
New directions in antiplatelet therapy
@nl
prefLabel
New directions in antiplatelet therapy
@ast
New directions in antiplatelet therapy
@en
New directions in antiplatelet therapy
@nl
P1476
New directions in antiplatelet therapy
@en
P2093
Dominick J Angiolillo
P304
P356
10.1161/CIRCINTERVENTIONS.111.966176
P407
P577
2012-06-01T00:00:00Z